Ticagrelor Tablet
Product Images NDC 67877-491

Each tablet contains 90 mg of ticagrelor. The usual adult dosage should be referred to the package insert. Certain precautions listed include keeping all medications out of the reach of children, storing at 25°C (77°F) with excursions permitted between 15-30°C (59-86°F), and keeping the container tightly closed. The manufacturer is Akem Laboratories Ltd. in Mumbai, India, and distributed by Ascerd Laboratories, LLC in Bedminster, NJ. The medication is available in a 60 tablet pack. It is recommended to dispense the accompanying Medication Guide to each patient. Additionally, there is a label note regarding UV varnish application on a 45 x 20 mm area.*

The given text provides detailed information about a study's characteristics, including treatment approaches, demographics, medical history, and outcomes related to different groups within the study. It covers details such as the percentage of participants from different geographic regions, age groups, treatment approaches, and medical history for conditions like diabetes and prior TIA/Stroke. Additionally, the text includes information on the outcomes of treatment with Ticagrelor and Clopidogrel, as well as the Hazard Ratios and 95% Confidence Intervals for these treatments. This information can be valuable for analyzing the effectiveness of different treatments and understanding how various factors may influence outcomes in a clinical study.*

This text appears to be a detailed report or data summary related to a medical study evaluating the effects of a treatment (likely Ticagrelor) on different groups of individuals based on various characteristics such as age, sex, weight, BMI, geographic region, medical history, and more. The data includes outcomes, percentages, confidence intervals, and hazard ratios for different subgroups, possibly comparing the treatment group with a placebo group. The study seems to focus on variables such as age, sex, race, weight, medical conditions like diabetes mellitus, coronary artery disease, and treatment history. It may be analyzing the efficacy and safety of Ticagrelor compared to a placebo in a clinical trial setting.*

This text provides information on drug interactions of Ticagrelor with other medications such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. It also includes recommended doses and potential adjustments. The text mentions that there are no dose adjustments needed for Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Digoxin, and Cyclosporine when taken with Ticagrelor, but there may be a need for adjustment with Tolbutamide.*

This text contains statistical data on the use of Ti90mg (probably referring to a type of medication) and Clopidogrel for patients with events, including the percentage at 12 months, hazard ratio (HR), confidence intervals (CI), and p-values. The data also presents the number of patients with events in each group at different time points over 360 days. This information appears to be part of a clinical study or trial evaluating the effectiveness of these medications.*

This text provides information about the interacting drug Ticagrelor. It lists different drugs and their effects when used together with Ticagrelor, categorizing them as strong, moderate, or potent CYP3A4 inhibitors, inducers, P-gP and CYP3A inhibitors. It also suggests dose adjustment recommendations, concomitant use advice, and specific doses for certain medications like Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl. The text includes information on mean effect and 90% CI as well as changes relative to the reference.*

This text appears to show data related to a study or clinical trial involving patients receiving different doses of a medication and a placebo over a period of at least 36 months. The text includes information about the number of patients experiencing events, hazard ratios, confidence intervals, p-values, and the number of patients at risk at different time points. The study seems to be comparing the effectiveness of different doses of the medication and the placebo on patient outcomes over time.*